Phase II study of paclitaxel, tegafur/uracil and folinic acid as first line treatment in metastatic or recurrent head and neck squamous cell carcinomas.

被引：0
|
作者：
Berrocal, A
Pastor, M
Caballero, C
Segura, A
Garcera, S
Oltra, A
Nogueron, E
Blasco, A
Lopez, P
Camps, C
机构：
[1] Univ Valencia, Gen Hosp, Valencia, Spain
[2] Hosp La Fe, E-46009 Valencia, Spain
[3] Hosp Ribera, Valencia, Spain
[4] Hosp Virgen Lirios, Alicante, Spain
[5] Hosp Albacete, Albacete, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页码：508S / 508S
页数：1
相关论文
共 50 条
  • [1] Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
    Hsieh, M-C.
    Wang, C-C.
    Yang, C-C.
    Yeh, S-A.
    Lien, C-F.
    Wang, C-C.
    Shih, Y-C.
    Tsai, Y-F.
    Hwang, T-Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S1350 - S1351
  • [2] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [3] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [4] Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
    Chen, San-Chi
    Chang, Peter Mu-Hsin
    Yang, Muh-Hwa
    ONCOLOGIST, 2016, 21 (05): : 537 - 538
  • [5] Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience
    Lin, JK
    Wang, WS
    Hsieh, RK
    Hsu, TC
    Chiou, TJ
    Liu, JH
    Fan, FS
    Yen, CC
    Lin, TC
    Jiang, JK
    Yang, SH
    Wang, HS
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (11) : 510 - 514
  • [6] Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Shin, DM
    Khuri, FR
    Glisson, BS
    Ginsberg, L
    Papadimitrakopoulou, VM
    Clayman, G
    Lee, JJ
    Ang, KK
    Lippman, SM
    Hong, WK
    CANCER, 2001, 91 (07) : 1316 - 1323
  • [7] Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study
    Stier, S
    Koll, C
    Neuhaus, T
    Fronhoffs, S
    Forkert, R
    Tuohimaa, A
    Vetter, H
    Ko, Y
    ANTI-CANCER DRUGS, 2005, 16 (10) : 1115 - 1121
  • [8] Palliative treatment with paclitaxel and tegafur oral in head and neck cancer (second line). A phase II study
    Pujol, E
    Redondo, LM
    Alonso, A
    Fernandez, A
    Freire, I
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 1109 - 1112
  • [9] A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob S.
    Hsu, Robert
    Villaflor, Victoria
    Riess, Jonathan
    Nieva, Jorge
    Krailo, Mark
    Gutkind, Silvio
    Colevas, Dimitri
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Paclitaxel and carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. A phase II study.
    Hiller, S
    Mergenthaler, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
12345